iclaprim and telavancin
iclaprim has been researched along with telavancin in 5 studies
Compound Research Comparison
| Studies (iclaprim) | Trials (iclaprim) | Recent Studies (post-2010) (iclaprim) | Studies (telavancin) | Trials (telavancin) | Recent Studies (post-2010) (telavancin) |
|---|---|---|---|---|---|
| 45 | 7 | 16 | 245 | 29 | 139 |
Research
Studies (5)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Micek, ST; Neuner, EA; Ritchie, DJ | 1 |
| Cabeza, J; Carrasco, C; Gutierrez, J; Sorlozano, A; Villegas, E | 1 |
| Cattoir, V; Daurel, C | 1 |
| Kollef, MH | 1 |
Reviews
3 review(s) available for iclaprim and telavancin
| Article | Year |
|---|---|
New antibiotics for healthcare-associated pneumonia.
Topics: Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Ceftaroline; Cephalosporins; Cross Infection; Doripenem; Glycopeptides; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Pneumonia, Bacterial; Pseudomonas Infections; Pyrimidines; Staphylococcal Infections; Teicoplanin | 2009 |
[Update on antimicrobial chemotherapy].
Topics: Acetamides; Aminoglycosides; Anti-Infective Agents; beta-Lactams; Carbapenems; Cephalosporins; Daptomycin; Doripenem; Drug Resistance, Bacterial; Ertapenem; Fluoroquinolones; France; Humans; Linezolid; Lipoglycopeptides; Minocycline; Oxazolidinones; Penicillins; Pyrimidines; Teicoplanin; Tigecycline | 2010 |
New antimicrobial agents for methicillin-resistant Staphylococcus aureus.
Topics: Aminoglycosides; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Glycopeptides; Humans; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Pyrimidines; Staphylococcal Infections; Teicoplanin | 2009 |
Other Studies
2 other study(ies) available for iclaprim and telavancin
| Article | Year |
|---|---|
Regulatory watch: Non-inferiority-trial discussions impact new drug applications.
Topics: Aminoglycosides; Anti-Infective Agents; Drug Approval; Drug Evaluation; Glycopeptides; Humans; Lipoglycopeptides; Pyrimidines; Therapeutic Equivalency; United States; United States Food and Drug Administration | 2009 |
Antimicrobial development in the era of emerging resistance.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Bacteria; beta-Lactams; Cephalosporins; Drug Approval; Drug Resistance, Bacterial; Glycopeptides; Humans; Lipoglycopeptides; Pyrimidines; Skin Diseases, Bacterial; Skin Diseases, Viral; Teicoplanin; United States; United States Food and Drug Administration | 2009 |